Difference between revisions of "Hypermagnesemia"

(Evaluation)
 
Line 6: Line 6:
 
==Clinical Features==
 
==Clinical Features==
 
*[[Nausea and vomiting]]
 
*[[Nausea and vomiting]]
*Loss of reflexes and diaphragmatic paralysis (at very high levels)
+
*Loss of reflexes and [[respiratory failure|diaphragmatic paralysis]] (at very high levels)
  
 
{| class="wikitable"
 
{| class="wikitable"
Line 26: Line 26:
 
*[[Renal Failure]]
 
*[[Renal Failure]]
 
*[[Lithium]]
 
*[[Lithium]]
*Volume depletion
+
*[[hypovolemia|Volume depletion]]
 
*[[Rhabdo]]
 
*[[Rhabdo]]
*IV Mg (goal in PET/eclampsia 5-7 mEq/L)
+
*IV Mg (goal in PET/[[eclampsia]] 5-7 mEq/L)
*Massive PO intake (laxative abusers, accidental Epsom salts)
+
*Massive PO intake ([[bulimia nervosa|laxative abusers]], accidental Epsom salts)
 
*Magnesium enemas<ref>Schelling Fatal hypermagnesemia. JR1. Clin Nephrol. 2000 Jan;53(1):61-5.</ref>
 
*Magnesium enemas<ref>Schelling Fatal hypermagnesemia. JR1. Clin Nephrol. 2000 Jan;53(1):61-5.</ref>
  

Latest revision as of 01:06, 29 September 2019

Background

  • High >3.5
  • Magnesium is an effective calcium channel blocker both extracellularly and intracellularly[1]
  • Intracellular magnesium profoundly blocks several cardiac potassium channels

Clinical Features

Mg Level Signs/Symptoms
2-3 Nausea
3-4 Somnolence
4-8 Loss of DTRs, muscle weakness
8-12 Respiratory depression
12-15 Hypotension, heart block, Cardiac Arrest, death

Differential Diagnosis

Evaluation

  • Magnesium level >3.5

Management

Disposition

See Also

References

  1. Rizzo MA, Fisher M, Lock JP. Hypermagnesemic pseudocoma. Arch Intern Med. 1993;153(9):1130.
  2. Schelling Fatal hypermagnesemia. JR1. Clin Nephrol. 2000 Jan;53(1):61-5.